COPD Exacerbation Suspected
Acute worsening of respiratory symptoms beyond normal day-to-day variation
All Pathways
Pulmonary MedicineEmergency
COPD Exacerbation Management (GOLD 2025)
COPD Exacerbation Management (GOLD 2025): COPD Exacerbation Suspected → Assess Exacerbation Severity → Hospitalization Indicated? → Outpatient Managemen...
Pathway Overview
13 steps
Algorithm Steps
13 total
01Start 02Decision Assess Exacerbation Severity
Evaluate symptoms, signs, and need for hospitalization
- Mild: Increased SOB, treated with SABDs only
- Moderate: Requires systemic steroids ± antibiotics
- Severe: Requires hospitalization or ED visit
- Assess: dyspnea at rest, RR, HR, SpO2, mental status
03Decision Hospitalization Indicated?
Assess need for admission
- Severe symptoms (dyspnea at rest, high RR, SpO2 <90%)
- Acute respiratory failure
- New physical signs (cyanosis, edema)
- Failure to respond to initial treatment
- Serious comorbidities (HF, arrhythmias)
- Insufficient home support
04Action Outpatient Management
For mild-moderate exacerbations
- Increase SABD: Salbutamol 2.5-5mg nebulized PRN
- Oral corticosteroids: Prednisone 40mg daily x 5 days
- Antibiotics if purulent sputum: Amoxicillin, Doxycycline, or Azithromycin
- Review inhaler technique
- Follow-up in 48-72 hours
05Outcome Discharge Planning
Criteria and follow-up
- Stable on usual medications for 12-24h
- Using inhalers correctly
- Ensure adequate home support
- Follow-up within 4-6 weeks
- Smoking cessation counseling
- Pulmonary rehabilitation referral
06Action ED/Hospital Initial Treatment
For moderate-severe exacerbations
- Controlled oxygen: Target SpO2 88-92%
- Bronchodilators: Salbutamol 2.5-5mg + Ipratropium 500mcg nebulized
- Systemic corticosteroids: Prednisone 40mg PO or equivalent IV
- Antibiotics if indicated (increased dyspnea + sputum purulence/volume)
- Consider prophylactic LMWH
07Decision ABG Assessment
Check arterial blood gas for respiratory failure
- pH <7.35 with PaCO2 >45 mmHg = Respiratory acidosis
- pH <7.25 = Severe acidosis - consider ICU
- PaO2 <60 mmHg on supplemental O2 = Severe hypoxemia
08Decision NIV Indicated?
Non-invasive ventilation criteria
- Respiratory acidosis (pH <7.35, PaCO2 >45)
- Severe dyspnea with accessory muscle use
- Persistent hypoxemia despite O2
- Contraindications: Cardiac/respiratory arrest, uncooperative, facial trauma
09Action Start NIV (BiPAP)
Non-invasive ventilation settings
- Initial settings: IPAP 10-12, EPAP 4-5 cmH2O
- Titrate IPAP for ventilation (↓PaCO2)
- Titrate EPAP for oxygenation (↑SpO2)
- Target: pH >7.35, SpO2 88-92%
- Reassess in 1-2 hours
10Decision NIV Response at 1-2h?
Assess response to NIV
- Good: pH improving, RR decreasing, patient comfortable
- Poor: No improvement or deterioration in pH, RR, mental status
11Warning ⚠️ Intubation/ICU
NIV failure or contraindicated
- NIV failure (no improvement in 1-2h)
- Decreasing consciousness
- Hemodynamic instability
- Unable to protect airway
- Respiratory arrest
12Action Continue NIV
Wean as tolerated
- Continue until pH normalized
- Wean IPAP gradually
- Transition to nocturnal NIV if needed
- Assess for long-term home NIV
- Path rejoins step 05Shared downstream outcome
13Action Medical Therapy (No NIV)
Continue treatment, close monitoring
- Continue bronchodilators q4-6h
- Corticosteroids: Complete 5-day course
- Antibiotics: 5-7 days if indicated
- Monitor SpO2, clinical status
- Daily ABG if initially abnormal
- Path rejoins step 05Shared downstream outcome
Guideline Source
Global Strategy for Prevention, Diagnosis and Management of COPD: 2025 Report
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address COPD-asthma overlap syndrome in detail
- Does not cover home ventilation decisions
- Antibiotic choice should be guided by local resistance patterns
- NIV settings require individual titration
Contraindicated Populations
pediatric
Applicable Regions
Global
Global: GOLD guidelines are internationally recognized; antibiotic selection per local patterns
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Calculator
Pulmonary Embolism Severity Index (PESI)
30-day mortality risk stratification for acute pulmonary embolism
Open page
Compare
AttendMe.ai vs DynaMed
See how this pathway workflow compares against DynaMed.
Open page
Commercial
Start free
Run the pathway in a live AttendMe account with citations and tracked usage.
Start free
Related Resources
Frequently Asked Questions
What is the COPD Exacerbation Management (GOLD 2025)?
The COPD Exacerbation Management (GOLD 2025) is a emergency clinical algorithm for Pulmonary Medicine. It provides a structured decision tree to guide clinical decision-making, based on Global Strategy for Prevention, Diagnosis and Management of COPD: 2025 Report.
What guideline is the COPD Exacerbation Management (GOLD 2025) based on?
This algorithm is based on Global Strategy for Prevention, Diagnosis and Management of COPD: 2025 Report (DOI: 10.1080/15412555.2025.2451613).
What are the limitations of the COPD Exacerbation Management (GOLD 2025)?
Known limitations include: Does not address COPD-asthma overlap syndrome in detail; Does not cover home ventilation decisions; Antibiotic choice should be guided by local resistance patterns; NIV settings require individual titration. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the COPD Exacerbation Management (GOLD 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free